Introduction
The promoter of the murine whey acidic protein gene (WAP-promoter) is activated by lactotrophic hormones and directs the temporal and spatial expression of the whey acidic milk protein. Activation occurs during late pregnancy (day 16) in mammary epithelial cells (MECs) of the lobuloalveolar unit (similar to the human terminal duct lobular unit, TDLU), and persists during lactation (Pittius et al., 1988a) . Owing to these properties, the WAP-promoter is often used to drive tissue-specific transgene expression in mouse MECs in order to study various processes in mammary gland function, development, or pathology Pittius et al., 1988b; Schoenenberger et al., 1988; Jhappan et al., 1993; Wagner et al., 1997; Li et al., 1998; Lazar et al., 2000) . Induction of an ectopic WAP-promoter often leads to a mosaic expression pattern in the mammary gland, ranging from 0-100% to that of the endogenous WAP-gene (Robinson et al., 1995) . The mosaic expression pattern has been attributed to position effects, which can be overcome, at least partially, by insulation of the WAP-transgene by matrix attachment region sequences (MARs) (McKnight et al., 1996) .
The variegated expression of transgenes in WAPtransgenic mice, however, also provides experimental advantages, as it creates transgenic animals with unique properties, depending on the level of transgene expression. In this regard, we previously reported the construction and characterization of WAP-T mice (Schulze-Garg et al., 2000) . These mice carry the SV40 early gene region under the control of the murine WAPpromoter. Upon induction by lactotrophic hormones they develop intraepithelial neoplasias, which further progress to invasive, but rarely metastatic mammary carcinoma. The transgenic mice are in a BALB/c genetic background, which favors the development of mammary carcinoma, as BALB/c mice carry mutations in the INK4A and the prdk loci (Zhang et al., 1998; Sherr, 2000) . The SV40 early region mainly serves to functionally eliminate the p53 and pRb tumor suppressors by binding to the large T-antigen, as shown by RNAi experiments (Voorhoeve and Agami, 2003) , and by changing the specificity of the phosphatase PP2A through interaction of the small t-antigen with the PP2A catalytic subunit (Chen et al., 2004) , thereby initiating tumor development. Owing to mouse linespecific mosaic expression of the transgene, several transgenic lines were obtained that differ in latency of tumor development upon induction, and in tumor progression, with highly transgene expressing lines showing the strongest phenotype (Schulze-Garg et al., 2000) .
It has been reported that in mammary carcinomas, mutations in the p53 gene, either alone or in conjunction with Erb-B2 (Her-2/Neu) overexpression, correlate with poor prognosis and resistance to certain chemotherapeutic treatments, and thus constitute a high risk factor for tumor patients (Goh et al., 1995; Aas et al., 1996; Borresen-Dale, 2003; Rahko et al., 2003) . This is attributed to a 'gain of function' phenotype of at least certain p53 hot spot mutations (reviewed in Deppert et al., 2000; Sigal and Rotter, 2000; Kim and Deppert, 2004) . To analyse the postulated causal relationship between mutant p53 (mutp53) expression and tumor progression, animal models should be extremely helpful. Such models should recapitulate human mammary tumorigenesis, and should allow the assessment of the postulated dominant-oncogenic functions of mutp53 in the absence of a wild-type (wt) p53, in order to differentiate between true oncogenic functions of mutp53 and a dominant-negative effect of mutp53 over wtp53.
As a tool for such studies, we constructed transgenic mice carrying murine mutant p53 transgenes harboring point mutations equivalent to the human tumor-derived hot spot mutations 248W and 273H (murine 245W and murine 270H, respectively). In order to distinguish transgenic mutp53 (m245W and m270H) from endogenous wild-type p53, a hemagglutinin (HA)-tag was fused to the transgene. The transgenes are under the control of the murine WAP-promoter, allowing their temporal and tissue-specific expression (WAP-mutp53 mice). These transgenic mice are also of a BALB/c genetic background, which predisposes females of heterozygous p53 þ /À mice to develop mammary carcinoma (Kuperwasser et al., 2000) . Here, we describe the construction and characterization of 23 WAP-mutp53 transgenic mouse lines. Only few lines were obtained, in which most of the induced MECs expressed the mutp53 transgene, most of the transgenic lines did not express mutp53 or expressed the transgene in less than 2% of the induced MECs. The expressing lines showed mouse line-specific mosaic expression patterns for the mutp53 transgenes. No correlation between the number of integration sites and transgene copy number influencing transgene expression could be found. We provide evidence that epigenetic mechanisms can affect the expression of the mutp53 transgene in individual mouse lines.
Results

Construction of WAP-mutp53 minigenes
Construction of the WAP-mutp53 minigenes is described in detail in Material and methods. Briefly, we constructed murine p53 minigenes carrying point mutations equivalent to human tumor-derived hot spot mutations (human mutp53 R248W 8 murine mutp53
R245W
, human mutp53 R273H 8 murine mutp53 R270H ). The transgenes were placed under the control of the murine WAPpromoter, leading to their expression in mouse MECs upon lactotrophic hormone induction (Tzeng et al., 1993) . The use of a minigene (i.e. a transgene carrying an intron-exon structure) has been previously shown to significantly enhance the expression of the transgene as compared to the use of a cDNA (Brinster et al., 1988; Lozano and Levine, 1991; McKnight et al., 1995) .
Point mutations were introduced into the original murine wild-type p53 (wtp53) minigene via PCR mutagenesis. We used vector pLTRp53cGwt (Eliyahu et al., 1985) , kindly provided by M Oren, which contains the entire murine p53 gene, except for exon I, introns 1 and 10. In order to distinguish transgenic mutp53 from endogenous wtp53, the coding sequence for the influenza HA-tag (Field et al., 1988) was fused via a flexible linker to the C-terminus of the mutp53 transgenes by PCR mutagenesis. The respective fragments were cloned into a murine WAP-promoter-carrying plasmid (pWAP-T; Tzeng et al., 1993) . Bidirectional sequencing of all exons and of exon/intron junctions of the mutp53 minigenes revealed that the desired mutations were obtained and that all other sequences were wild type. The resulting mutp53 constructs are schematically depicted in Figure 1a .
Generation of WAP-mutp53 transgenic mice
Transgenic mice were generated by microinjection of linearized WAP-mutp53 DNA into the male pronucleus of C57BL/6-BALB/c hybrid zygotes. The offspring resulting from 15 microinjection experiments was analysed for transgene integration by PCR of genomic DNA from tail biopsies. PCR was performed using primers covering regions of the p53 exon IX and the HA-tag sequence, thereby allowing a differentiation between endogenous and transgenic p53 genes (see Figure 1a) . A set of 32 transgenic founders was generated and bred into the BALB/c genetic background. These mutp53 transgenic mouse lines have been assigned the following nomenclature: BALB/c WAP-mutp53 R245W -W1, y, WAP-mutp53 R270H -H1, y, abbreviated as lines W1, y and lines H1, y, respectively (Table 1) .
After breeding, 10 (67%) out of 15 potential WAPmutp53 R245W transgenic founder animals and 13 (76%) out of 17 potential WAP-mutp53 R270H transgenic founder animals showed germline integration of the transgene constructs. Four (27%) of the 15 WAP-mutp53
R245W
, and four (24%) of the 17 WAP-mutp53 R270H transgenic lines did not transmit the transgene, either because the transgene was not integrated into the germ line, or because of infertility of the founder. One male founder carried the transgene on the y-chromosome, and therefore also was not suitable for our intended investigations.
Characterization of WAP-mutp53 transgenic lines
After hemizygous breeding into a BALB/c background, transgenic females from 23 individual transgenic Mutant p53 expression in WAP-mutp53 transgenic mice F Krepulat et al WAP-mutp53 lines of the first generation (F1) were analysed. Transgene expression was examined in mammary gland tissues and other organs both by RT-PCR and by immunohistochemistry (IHC) at day 5 postpartum (day 5 pp). Nontransgenic littermates served as controls. Mutp53 expression could not be observed during and after involution as well as in nulliparous controls with exception of the transgenic lines W1, W10, and H8. These three lines with relatively high levels of mammary gland tissue-specific mutp53 expression display a lactotrophic hormone-independent, but tissuespecific transgene expression pattern (see below). Nine out of 23 transgenic lines analysed by RT-PCR showed specific transgene transcription in mammary gland tissue and did not express mutp53 in other tested organs, like liver, spleen, kidneys, heart, or lungs ( Figure 1b) . In four lines, mutp53 was weakly transcribed additionally in cardiac and renal tissue. Mutp53 transcription could not be detected in nine lines and one line transcribed mutp53 in a tissues-independent fashion (Table 1) .
The transgene expression patterns were further analysed by IHC, revealing a mosaic expression pattern for mutp53 in mammary epithelium in the various WAP-mutp53 transgenic lines (Table 2) . Seven out of 23 WAP-mutp53 transgenic lines expressed mutp53 in an intermediate or high percentage of MECs, whereas six lines expressed mutp53 in a low proportion of cells, and nine lines did not show any mutp53 expression in mammary gland tissue (Figure 2d-f) . Mutp53 was localized in the cytoplasm as well as in the nucleus of MECs. Transgenic lines W12 and W10, carrying a point mutation at amino-acid position 245, as well as transgenic lines H3 and H8, carrying a point mutation at amino-acid position 270, showed a strong mutp53 expression in about 90-95% of MECs (Figure 2f ). Intermediate mutp53 expression was observed in two transgenic lines with a mutation in codon 245 of the Figure 1 (a) WAP-mutp53 transgene constructs under the control of the murine whey acidic protein (WAP-) promoter containing mutp53 R245W(*) and mutp53 R270H(x) point mutations. Primers used in studies are shown by arrows. Transgene screening was performed by using murine p53 exon IX-specific and HA-tag sequence-specific primers leading to a 1075 bp PCR product. A Southern DNA probe (762 bp) was amplified with primers in p53 introns 3 and 4. Transcription of mutp53 was analysed by RT-PCR using murine p53 exon VI-specific and HA-tag sequence-specific primers leading to a 628 bp PCR product (for details, see Material and methods). (b) Tissuespecific transcription of mutp53 in lactating mammary glands of BALB/c WAP-mutp53 mice (F1 generation, day 5 pp). Using a pair of primers complementary to murine p53 and HA-tag sequences, mutp53 transgene transcription was detected in mammary glands and not in other tissues. Control RT-PCR with murine p53-specific primers (586 bp) reveals the integrity of RNA. Lanes: cervical (1), first thoracal (2), second thoracal (3), abdominal (4) and inguinal mammary gland (5), liver (6), kidney (7), spleen (8), heart (9), lung (10), water as negative control (À), cDNA of mutp53 transcribing mammary gland as positive control ( þ ) and 100 bp DNA standard (M.W.) Negative 1-10 a Key for tissue specimens: lactating cervical (1), first thoracal (2), second thoracal (3), abdominal (4) and inguinal mammary gland (5) of day 5 pp: liver (6), kidney (7), spleen (8), heart (9), lung (10) Mutant p53 expression in WAP-mutp53 transgenic mice F Krepulat et al transgene, W1 with 50-60% expression in a disseminated pattern, and W15, with a more focal accumulation of mutp53-expressing MECs (ca. 20%). Expression of mutp53 in W15 was extremely variable, with part of the cells showing very strong expression, whereas others disclosed a very faint mutp53 tagging. H12, another transgenic line with mutation in codon 270 of the transgene, displayed mutp53 expression in 40-50% of the MECs. Low mutp53 expression in less than 2% of MEC's was observed in two lines with a point mutation in codon 245 (W4, W11) of the transgene, and in four lines with a point mutation in codon 270 (H2, H9, H15, H16). Morphology of glandular tissue during end stage of involution (day 50 pp) appears normal in mutp53 transgenic mice with heterogeneous mutp53 expression compared with wild-type control (Figure 2g-j) .
Stability of mutp53 expression patterns in transgenic mice
Position effects have been implicated in explaining the mosaic expression pattern of transgenes driven by an ectopic WAP-promoter in transgenic mice. It also has been reported that these effects depend on integration sites and transgene copy number within repeat integrations (Pittius et al., 1988a; Burdon et al., 1991) . To get an idea on whether a certain integration pattern might correlate with a specific expression pattern of the mutp53 transgenes, we selected WAP-mutp53 mouse lines differing in their expression patterns: one nonexpressing line, H22, one low expressing line, W4, three intermediate expressing lines W1, W15 and H12, and four high expressing mouse lines H3, H8, W10, and W12. Southern blotting of BamHI restricted genomic DNA from liver tissue were performed using a 762 bp probe (spanning p53 from intron 3 to intron 4, see Figure 1a ) detecting differentially the endogenous wtp53 gene and the mutp53 transgenes. Furthermore, the blot allowed the detection of direct repeats of the mutp53 transgenes, thereby enabling an estimate of the mutp53 transgene copy number. Figure 3 shows a representative example, comparing Southern blots of DNAs from the F1 generation with those from F4 to F8 generations of the same mutp53 transgenic lines.
Taken together, neither the number of integration sites, nor the copy number of integrated transgenes correlated with the mutp53 transgene expression pattern in the F1 generation (Table 3) . High mutp53 expressing lines W10, W12, H8, and H3 differ in transgene copy number from 31 to 1; similarly, none and low expressing lines H22 and W4 show copy numbers between 19 and 3.
Comparison of the integration patterns of the mutp53 transgenes after 4-8 generations of hemizygous breeding with BALB/c mice revealed that the integration patterns were not yet stable (Table 3 ). This instability of transgene integration and copy number was reflected by changes in mutp53 expression patterns. Approximately half of all lines analysed (W1, W4, W10, W12, W15, H3, H8, H12, and H22) displayed changes in their mutp53 expression pattern, as demonstrated by HA-tag immunostaining. So far, lines W1, W10, W15, H8, and H22 lost between 0 and 40% of their respective mutp53 transgenes, but remained stable with respect to mutp53 expression. However, three lines (W12, H12, and H3) lost transgene copies that most likely were responsible for mutp53 expression, leading to reduced or even no mutp53 expression at all. After several generations of . Although being independent of lactotrophic hormone induction, mutp53 expression is still confined to MECs in a tissue-specific manner. The tissue-specific induction of the WAP-promoter in MECs in the absence of lactotrophic hormones possibly indicates that expression from the WAP-promoter in mutp53 transgenes in MECs is regulated by additional parameters, like, for example, the surrounding chromatin structure . Lactotrophic hormone-independent expression of mutp53 transgenes could also be obtained in other In all, 10 mg of genomic DNA was digested by BamHI. DNA of transgenic lines H3 and W12 was additionally digested by EcoRI. A DNA probe spanning p53 intron 3 and intron 4 was used for hybridization. Autoradiograms show a 3.9 kb internal fragment derived from the mutp53 transgene as well as a 5.7 kb fragment derived from the endogenous wtp53 gene and several integration-dependent fragments. Lanes: genomic DNA of BALB/c wt, lines H3, H8, H12, H22, W1, W4, W10, W12, and W15; 1 kb DNA standard (M.W.); plasmid DNA of WAP-mutp53 R245W digested with BamHI and EcoRI leads to the positive signal ( þ ) (Table 2) , in which mutp53 transgene expression is under the strict control of the WAP-promoter. Figure 4 shows the morphological and immunohistochemical analysis of mammary tissue of an induced W4 mouse, 5 days pp. The morphology of the gland epithelium is normal (Figure 4a ), about 2% of the epithelial cells stain positive for mutp53, either with polyclonal rabbit antip53 antibody (Figure 4b) , or with the anti-HA-tag antibody (Figure 4c ). No mutp53 staining could be detected in mammary tissue of noninduced mice (Figure 4d ), and in mammary tissue after complete first involution (60 days pp, Figure 4e ). After a second parturition, the mammary tissue remains morphologically unchanged. However, a focal increase in the number of mutp53-positive MECs can be observed (Figure 4f ). Furthermore, mutp53-positive cells no longer are randomly distributed, but appear to cluster in individual alveoli. The phenomenon becomes even more pronounced after a fourth parturition (Figure 4g ). Again no morphologic alterations are seen, but a very strong mutp53-staining appears in groups of glandular acini. In the tagged alveolar structures, nearly all epithelial cells are positive, whereas most of the other alveoli remain negative. The clustering of mutp53-expressing cells in individual alveoli suggests that such cells derive from progenitor cells that can express mutp53 after lactotrophic hormone induction and survive involution. Foci of mutp53-expressing epithelial cells can be detected in the mammary epithelium of a multiparous animal line W4, 10 months pp (Figure 4i ), indicating that expression of mutp53 after multiple inductions is no longer controlled by lactotrophic Figure 4 Phenotypic aspects of the low expressing mutp53 line W4 during virgin state, lactation, involution, and after multiple parturitions (F1 generation). After induction, the morphology of the glandular epithelium appears normal (a), about 2% of the epithelial cells stain positive for mutp53, either with polyclonal rabbit anti-p53 antibody (b), or with the anti-HA-tag antibody (c). No mutp53 staining can be detected in mammary tissue of a noninduced virgin mouse (d), and after complete involution (e). After a second parturition, the mammary tissue remains morphologically unchanged. However, a focal increase in the number of mutp53-positive MECs can be observed (f). Expansions of HA-tag-positive epithelial foci encompassing clusters of labeled alveoli after a fourth parturition become visible (g). The mammary epithelium of a multiparous animal 10 months pp appears normal; the depicted hyperplasia is age dependent and without atypia (h). Under this condition, foci of mutp53-expressing epithelial cells can be detected (i, arrows), indicating that expression of mutp53 after multiple inductions is no longer controlled by lactotrophic hormones. hormones. Despite persistent mutp53 expression, the mammary epithelium is morphologically inconspicuous (Figure 4h ). The finding is in accordance with previous reports on WAP-mutp53 (mR172H) mice indicating that mutp53 expression as such does not induce mammary carcinogenesis (Li et al., 1998; Murphy and Rosen, 2000) .
Expression of silent mutp53 transgenes is activated in WAP-T Â WAP-mutp53 bitransgenic mice
Our data suggest that the expression of mutp53 transgenes in WAP-mutp53 mice is controlled by mouse line-specific epigenetic factors (like e.g. location of integrations sites in the mouse genome), leading to intralineage stable, but interlineage heterogeneous mutp53 expression. In addition, however, other epigenetic mechanisms, such as modifications associated with alterations of the chromatin structure, which might occur in MECs during pregnancy and mammary gland involution, also seem to affect mutp53 transgene expression. Therefore, it was of interest to find conditions that would lead to chromatin remodeling in MECs, thereby allowing modulation of mutp53 transgene expression. Analysis of epigenetic mechanisms controlling transgene expression is feasible in vitro, as epigenetic alterations can be easily induced by substances influencing chromatin structure (Cameron et al., 1999; Bartoli et al., 2003) . However, most of these substances are rather toxic and thus are not suited for use in animal experiments (Gottlicher et al., 2001; Kramer et al., 2003; Zgouras et al., 2004) . Furthermore, exogenous application of chromatin-modifying agents to animals cannot target epigenetic alterations specifically to mammary epithelial cells. It has been reported that expression of SV40 Tantigen causes altered methyl-and histone acetyltransferase activity (Slack et al., 1999; Valls et al., 2003) , suggesting that T-antigen induces chromatin remodeling (see also Discussion). Therefore, we asked whether Tantigen might affect the expression of silent mutp53 transgene(s) by chromatin remodeling. To first test this idea in vitro, the mutp53 (R270H) minigene was cloned into the pCIneo vector, substituting the WAP-promoter by a CMV-promoter, and then transfected into BALB/c 3T3 cells. Stably transfected cell clones were obtained after neomycin selection. Like in our in vivo transgenic experiments, only few clones were obtained that expressed the mutp53 transgene to a significant extent, arguing that epigenetic mechanisms control transgene expression also in vitro. To test the effect of SV40 Tantigen on mutp53 transgene expression, we abortively infected cells of a low mutp53-expressing (3T3mutp53 C2) and an intermediate mutp53-expressing clone (3T3mutp53 C6) with SV40. These clones were analysed for T-antigen and mutp53 expression 34 h postinfection by Western blotting. Untransfected 3T3 cells served as control. Figure 5a shows that T-antigen was expressed in all infected cells at approximately similar levels. Mutp53 was specifically detected by the HA-tag antibody only in the stably transfected cells. Comparison of mutp53 levels in uninfected and infected 3T3mutp53 C2 and C6 cells, respectively, showed a significant increase in infected cells, best seen in the low expressing C2 cells. The conclusion that augmented mutp53 levels in 3T3mutp53 C2 and C6 cells after SV40 infection result from SV40 T-antigen-induced chromatin remodeling was further supported by experiments in which we analysed mutp53 expression after treating 3T3mutp53 C2 and C6 cells with chloroquine. Chloroquine induces global chromatin structure alterations without inducing DNA damage (Bakkenist and Kastan, 2003) . Figure 5b shows that treatment of 3T3mutp53 C2 and C6 cells with 50 mM chloroquine for 24 h already led to a significantly enhanced mutp53 expression, which further strongly increased 48 h after chloroquine treatment.
Our finding that T-antigen expression led to an enhanced expression of silent mutp53 transgenes in vitro prompted us to investigate the effects of T-antigen expression on silent mutp53 transgenes in vivo. To this end, we crossed mice of the WAP-T1 line (Schulze-Garg et al., 2000) , which express T-antigen in B90% of MECs, with mice of the line WAP-mutp53 R270H -H22, which does not express mutp53 after induction. Bitransgenic females were selected by PCR analyses of genomic DNA from tail biopsies. At the age of 8 weeks, bitransgenic females were mated with wt BALB/c males. At 5 days pp, the mammary glands were dissected and analysed for mutp53 and SV40 T-antigen expression by 
RT-PCR and by immunohistology. RT-PCR analysis
revealed that now both transgenes were transcribed specifically in the mammary glands (Figure 6 ), but not in other tissues, demonstrating tissue-specific re-expression of the silenced mutp53 transgene under the influence of SV40 T-antigen. Mutp53 and SV40 T-antigen could be readily demonstrated in the mammary gland tissue by double labeling immunofluorescence microscopy ( Figure 7 ). The majority of the epithelial cells stained positive for SV40 T-antigen (panels b and e), whereas only a few cells (B1%) stained positive for mutp53. Panels a and d disclose the heterogeneous expression of mutp53, with mutp53 expression strictly in the cytoplasm (a) or predominantly nuclear (d). No mutp53-expressing cell could be detected, which did not coexpress T-antigen. Strong immunostaining of Tantigen was seen in all mutp53-expressing cells, suggesting that such expression is necessary (though not sufficient) for induction of mutp53 expression.
Expression of SV40 large T-antigen leads to global chromatin reorganization
To get insight into how expression of T-antigen might contribute to reactivation of silenced mutp53 transgenes, we established mammary epithelial cell cultures from a murine ductal mammary carcinoma that had developed in bitransgenic WAP-T1 Â WAP-mutp53
R270H
-H22 mice after induction. The cells could be propagated in the presence or absence of lactotrophic hormones, and showed a hormone-dependent expression of the transgenes (data not shown). Most of the tumor cells exhibited an epithelial phenotype, as demonstrated by plasma membrane staining with an anti-EpCam antibody (Figure 8a ). Upon addition of lactotrophic hormones, about 90% of the tumor cells stained positive for T-antigen, whereas expression of mutp53 was R270H -H22 bitransgenic mice (day 5 pp). Mutp53 transgenespecific RT-PCRs display a transgene-specific transcription (628 bp) in mammary glands and not in other tissues using a pair of primers complementary to murine p53 and HA-tag (a). T-antigen transgene-specific RT-PCRs show that T-antigen (2120 bp) is specifically transcribed in mammary glands and not in other tissues using a pair of primers complementary to SV40 large Tantigen (b). Lanes: 100 bp DNA standard (M.W.), cervical (1), first thoracal (2), second thoracal (3), abdominal (4) and inguinal mammary gland (5), liver (6), kidney (7), spleen (8), heart (9) and lung (10) Mutant p53 expression in WAP-mutp53 transgenic mice F Krepulat et al detected only in 1-5% of the T-antigen-bearing cells (Figure 8b1-2) .
T-antigen is tightly bound to the karyoskeleton (Schirmbeck and Deppert, 1991; Schmitt and Mann, 1987) through interaction with nucleolin (Seinsoth et al., 2003) and lamin C (Klawitz et al., 2001) . This protein-chromatin interaction may directly or indirectly influence global chromatin organization, which prompted us to analyse intranuclear distribution of centromeric and telomeric heterochromatin by in situ hybridization. Using a murine pan-centromeric (gsatellite) probe, we found that the centromeres in cells without or with very low T-antigen expression are physically in contact with each other, forming the socalled chromocenters, with numbers varying from 10 to 20 (Figure 8c ). In contrast, in the nuclei of all cells expressing high levels of T-antigen, the numbers of centromere clusters increased by 2-3 times, but their size was reduced, indicating partial dissociation of the chromocenters resulting from a global change in chromatin structure. The notion of a global chromatin remodeling function of T-antigen was further substantiated by investigating the spatial arrangement of telomeres. In cells expressing T-antigen, both proximal and distal telomere ends of acrocentric mouse chromosomes seem to be in close contact with the centromere clusters ( Figure 8e ). In contrast, T-antigen-negative nuclei exhibited numerous telomeres distant from centromere clusters (Figure 8d ).
Discussion
Many transgenes display a mosaic expression pattern both in cell culture in vitro and in transgenic animals in vivo. However, the phenomenon of variegated expression is not restricted to transgenes, but can also be observed for (over-) expressed endogenous genes during tumorigenesis (Hanash, 2004 ). An important example is the expression of mutp53, which is very heterogeneous in various stages of tumor progression, despite the fact that all tumor cells carry the respective mutation in the p53 gene (Ebina et al., 2001) . So far, neither the mechanisms leading to mosaic expression, nor its biological implications, for example, for tumor development and progression, are known.
In this study, we report the construction and characterization of mutp53 transgenic BALB/c mouse lines. The mutp53 minigenes carry point mutations equivalent to the human tumor-derived hot spot mutations R273H and R248W (mR270H and mR245W, respectively), which comprise the two most 1992; , and was also observed in our WAP-T mice (unpublished observation). The expression pattern was stable in about half of the analysed mutp53 transgenic lines over the 4-8 generations analysed so far, suggesting that the specific expression pattern is 'programmed' within the individual mouse line, while the changes in the expression patterns of other lines over time was accompanied by the loss of integrated copies. The mosaic expression pattern of transgenes has been attributed to various parameters, including position effects, caused by transgene integration (Pittius et al., 1988a; Burdon et al., 1991) , and copy number of transgene repeats (Krnacik et al., 1995) . Although genetic analysis of our mice by Southern blotting did not reveal any correlation with numbers of integration sites and copy numbers of the transgene, the mouse linespecific and genetically stable transgene mosaic expression patterns can be best explained by events that epigenetically program expression, for example, integration of the transgenes at sites that differently affect chromatin structure in and around the transgenes. Such a mouse line-specific event then might result in a certain 'probability' for transgene expression upon induction, leading to the described mouse line-specific mosaic expression pattern. In addition to epigenetically fixed mosaic expression patterns, several observations indicated that these patterns can be influenced by other epigenetic mechanisms: (1) lactotrophic hormone-independent, but promoter-and cell-type-specific mutp53 transgene expression was observed in the intermediate expressing line W1 and in the high expressing lines W10 and H8; (2) in low and intermediate expressing lines, control by lactotrophic hormones was lost after repeated inductions, most likely reflecting the changes in mammary gland tissue morphology observed in multiparous animals; (3) in the low mutp53-expressing line W4, repeated inductions led to the accumulation of mutp53-expressing cells in individual lobuloalveolar units, suggesting the existence of mutp53-expressing progenitor cells that survive involution.
If indeed mutp53 expression in the WAP-mutp53 mice can be influenced by epigenetic mechanisms, we reckoned that induction of epigenetic alterations in epithelial cells of the mammary gland should lead to modified mutp53 transgene expression. As most substances that easily induce epigenetic alterations in vitro by influencing chromatin structure (Gottlicher et al., 2001; Kramer et al., 2003; Zgouras et al., 2004) are not suited for use in animal experiments, we investigated the possibility of SV40 T-antigen as a chromatin remodeling factor. So far it has been documented that SV40 T-antigen is indirectly involved in chromatin remodeling through modulation of CBP histone acetyltransferase activity (Valls et al., 2003) , and elevation of DNA methyltransferase activity (Slack et al., 1999) . In SV40 infected and transformed cells, T-antigen tightly associates with the chromatin and the nuclear matrix (Schirmbeck and Deppert, 1991; Schmitt and Mann, 1987; Staufenbiel and Deppert, 1983) , and interacts with nucleolin (Seinsoth et al., 2003) and lamin C (Klawitz et al., 2001) . T-antigen thus could directly or indirectly influence chromatin organization at a global level. In addition, the chromatin unwinding activity of T-antigen, required for viral replication (Milavetz, 2002; Jiao and Simmons, 2003; Li et al., 2003; Simmons et al., 2004) , might also contribute to the chromatin remodeling activity of T-antigen. Testing the effect of T-antigen on the expression of stably integrated silent mutp53 transgenes in BALB/c 3T3 cells in vitro indeed showed a significant increase in mutp53 expression. Our finding that mutp53 expression from silent mutp53 transgenes could also be induced by chloroquine, a chromatinmodifying agent (Bakkenist and Kastan, 2003; Zhou et al., 2002) , strongly supports our conclusion that expression of silent mutp53 transgenes after abortive infection of cells with SV40 is mediated by a T-antigen remodeling activity.
We next asked whether crossing WAP-T mice into WAP-mutp53 mice would allow tissue-specific chromatin remodeling via the chromatin remodeling activity of the transgenic SV40 T-antigen. Crossing of the T-antigen highly expressing line WAP-T1 (B90% T-antigen-positive MECs upon induction) with line H22 (not expressing mutp53) indeed led to re-expression of the silenced mutp53 transgene in about 1-2% of the induced cells in bitransgenic animals. Analysis of the effects of SV40 T-antigen on the spatial organization of centromeres and telomeres in mammary carcinoma cells derived from a bitransgenic WAP-T1 Â WAPmutp53 R270H -H22 mouse provided an evidence for a global chromatin reorganization in cells expressing T-antigen, which contributes to declustering of centromeric heterochromatin as well as physical association of proximal with distal telomeres. The data are the first direct demonstration of a chromatin remodeling activity of SV40 T-antigen in vivo. Further studies are required Mutant p53 expression in WAP-mutp53 transgenic mice F Krepulat et al to better characterize this activity and to understand its physiological role in SV40 infection and cellular transformation.
It still remains enigmatic, why only 1-2% of the induced cells re-expressed the mutp53 transgene, while B90% of the cells expressed SV40 T-antigen. Figure 7 , panels c and f, suggests that high level expression of SV40 T-antigen is an important, although apparently not sufficient parameter for re-expression of the silent transgene, as only cells with a high level of T-antigen expression coexpressed mutp53. In addition, one has to assume that epigenetic mechanisms silencing the mutp53 transgene, and/or the degree of silencing may slightly vary from cell to cell. The assumption might also explain the variegated expression pattern for mutp53 in induced cells of different transgenic lines.
The WAP-mutp53 mice described here mimic the often variegated expression of mutp53 in many tumors and thus may constitute a model for analysing parameters altering mutp53 expression during tumor development and progression when crossed into WAP-T mice. Specifically, they might provide a suitable model to analyse, why in normal cells of some Li-Fraumeni patients only the wild-type p53 allele is expressed, while the mutant p53 allele is silent (Felix et al., 1993; Horio et al., 1994) , and what may cause activation of its expression at the onset of malignant disease development.
Materials and methods
Construction of WAP-mutp53 expression vectors
The original murine wtp53 minigene was obtained from pLTRp53cGwt (Eliyahu et al., 1985) . In order to distinguish transgenic mutp53 from endogenous wild-type p53; a HA-tag was fused to the transgene. The coding sequence for this HAtag (AYDPVDYPY) was fused by PCR mutagenesis via a flexible linker of two glycins to the C terminus of murine p53 (p53 exon VI forward primer: 5 0 -gggtggaaggaaatttgtatcccg-3 0 , p53 exon XI reverse primer, including additionally the HA-tag coding sequence: 5 0 -gaattcagatcttcaggcgtagtcgggcacgtcgtagggg tagccgccgtctgagtcaggccccactttc-3 0 ). The PCR mix was composed of 100 ng plasmid-DNA (pLTRp53cGwt), 0.5 mM of each of the forward and reverse primer, 0.2 mM dNTP-mix, 0.05 U/ml Herkulaset DNA Polymerase (Stratagene), and 1 Â PCR-buffer. PCR was carried out after an initial denaturation for 35 cycles (30 s at 921C, 1 min 30 s at 601C, 3 min at 721C). The amplified PCR product of murine p53 exon VI to the HA-tag was subcloned in pUC18 to murine p53 Exon II-VI after DraIII restriction.
Mutations at codon 245 in p53 exon VII and at codon 270 in exon VIII were introduced by unique site elimination (U.S.E.) mutagenesis in the murine wtp53 genomic minigene. Mutagenesis was performed as described in manufacturer's protocol using forward primer: 5 0 ggcatgaacTgGcgacctatcc3 0 to exchange arginine (R) with tryptophan (W) at amino-acid position 245 and using forward primer: 5 0 -gctttgaggttcAtgtttgtgcc-3 0 to exchange arginine (R) with histidine (H) at position 270 in combination with a reverse selection primer: 5 0 -gacttggttgacgcgtcaccagtcacag-3 0 to substitute the ScaI restriction site with MluI in pUC18. Owing to different nucleotide triplet usage in different species, two nucleotides of codon 245 had to be exchanged in order to generate a W-mutation, as in human tumor-derived hot spot p53 point mutation 248. Each construct was cloned into a murine WAP-promoter carrying plasmid (pWAP-T) in order to place the mutp53 minigenes under the control of murine WAP regulatory sequences. This plasmid (Tzeng et al., 1993) , kindly provided by Professor Graessmann (University of Berlin), carries the SV40 early region (BglII-BamHI, 2.7 kb) under the control of the 1.6 kb murine WAP-promoter fragment (BglII-KpnI) and SV40 polyadenylation site. After Acc65I restriction, Klenow fill-in followed by BclI restriction SV40 early region was substituted by each of these mutp53 minigene constructs after EcoRI restriction, Klenow fill-in followed by BglII restriction, to generate WAP-mutp53 R245W and WAP-mutp53 R270H plasmid DNA.
Generation and screening of WAP-mutp53 transgenic mice
Transgenic mice were generated essentially as described elsewhere (reviewed in Hogan et al., 1986) . In short, linear WAP-mutp53 DNA (5.9 kb), excised with EcoRI and SalI from pUC18, was microinjected in fertilized C57BL/6-BALB/c hybrid zygotes. Each linear WAP-mutp53 DNA was injected at a concentration of 72.5 ng DNA/ml microinjection buffer (10 mM Tris-HCl pH 7.6, 0.1 mM EDTA), followed by implantation into pseudopregnant foster mice. A total of 100-150 zygotes were microinjected with WAP-mutp53 transgene DNA in each of 15 different microinjection experiments. A total of 30-70 vital embryos were transferred in each microinjection experiment into four to five foster mice. The transgene was detected in 32 (12%) of 271 pups born.
Potential transgenic animals were analysed by PCR of genomic DNA from tail biopsies using forward primer complementary to murine p53 exon IX: 5 0 -gatggagagtatttcaccctcaag-3 0 and reverse primer specific for the HA-tag sequence: 5 0 -caggcgtagtcgggcacgtcg-3 0 , which generate a 1075 bp product. PCR was performed as follows: 1 ng/ml genomic DNA, 0.5 mM of each primer, 0.2 mM dNTP-mix, 0.02 U/ml Taq DNA Polymerase (Eppendorf), and 1 Â PCRbuffer. PCR program: 921C for 2 min, followed by 35 cycles of 30 s at 921C, 45 s at 621C, and 1 min at 721C, followed by an additional 5 min at 721C. Resulting WAP-mutp53 transgenic lines are continuously bred as hemizygotes on the BALB/c genetic background.
Southern blot analysis
Positive transgenic lines in the generations F1 and at least F4 were examined by Southern hybridization. In all, 10 mg of genomic DNA, isolated from liver, was digested by BamHI. Transgenic lines H3 and W12 were additionally digested by EcoRI. A murine p53-specific DNA probe (762 bp), amplified by PCR, using p53 intron 3 forward primer: 5 0 -gccatcacctcactgcatggac-3 0 and intron 4 reverse primer: 5 0 -gcctcgaactcacagagatggc-3 0 , was used for hybridization. Autoradiograms were quantified by densitometry. Counts over background in each band were converted into transgene number by comparison with wtp53.
Animals
All mice were housed and handled in accordance to official regulations for care and use of laboratory animals and maintained under SPF conditions. Transgenic mice were kept under barrier conditions with a 12 h light/dark cycle and access to food and water ad libitum.
Analysis of transgene expression
Transgenic females were mated in order to induce mutp53 expression via lactotrophic hormones during pregnancy and lactation. The date of birth was counted as day 1 of lactation. Transgene expression during lactation, involution and in nulliparous animals was analysed in mutp53 transgenic lines as well as in age-matched nontransgenic littermates. Animals were euthanized by ether to dissect mammary glands, liver, spleen, kidneys, heart, and lungs. Tissues were snap-frozen and stored in liquid nitrogen until use, as well as fixed in 4% formaldehyde containing 1% acetic acid.
RNA extraction and analysis
RNA was isolated by homogenization of frozen tissue with a Polytron (Kinematica) homogenizer using the peqGOLD RNAPuret (Peqlab) protocol as described by the manufacturer (1 ml/50 mg mammary gland). Briefly, cDNA was generated from 1 mg of total cellular RNA from the mammary glands and other organs using the ThermoScriptt RT-PCR System (Invitrogen). RNA was denatured with 2.5 mM of oligo(dT) 20 in DEPC-treated water for 10 min at 721C and transcribed in a 20 ml reaction mixture containing 1 Â cDNA synthesis buffer, 5 mM dithiothreitol, 1 mM dNTP mix, 2 U/ml RNaseOUTt, and 0.75 U/ml ThermoScript-RT for 50 min at 521C. The reaction was terminated by heating 15 min at 751C. RNA was removed by RNaseH for 30 min at 371C. The mutp53 transgene-specific PCR mix (20 ml) was composed of 1 ml cDNA solution, 0.075 mM of each of the forward (murine p53 exon VI: 5 0 -gggtggaaggaaatttgtatcccg-3 0 ) and reverse (HAtag: 5 0 -caggcgtagtcgggcacgtcg-3 0 ) primers, 200 mM dNTP mix, 2 mM dithiothreitol, 1 Â PCR-buffer and 0.05 U/ml Taq DNA Polymerase (Eppendorf). PCR was carried out for 30 cycles (30 s at 921C, 20 s at 661C, 35 s at 721C) to generate a 628 bp PCR product. A T-antigen transgene-specific PCR mix (20 ml) was composed of 1 ml cDNA solution, 0.075 mM of each of the SV40 forward (5 0 -gtttcaggttcagggggaggtg-3 0 ) and reverse (5 0 -ggataaagttttaaacagagaggaatc-3 0 ) primers, 200 mM dNTP mix, 2 mM dithiothreitol, 1 Â PCR-buffer, and 0.05 U/ml Taq DNA polymerase (Eppendorf). PCR was carried out for 35 cycles (30 s at 921C, 30 s at 621C, 2 min 10 s at 721C) to generate a 2120 bp PCR product. For a control PCR, the forward (murine p53 exon VI: 5 0 -gggtggaaggaaatttgtatcccg-3 0 ) and reverse (murine p53 exon XI: 5 0 -gtcaggccccacttcttgacca-3 0 ) primers were used instead and PCR was carried out for 35 cycles (30 s at 921C, 30 s at 621C, 40 s at 721C) to generate a 586 bp PCR product. Primers extend across at least an intron, so an eventual DNA contamination would not pose a significant problem.
Mammary gland whole-mount staining
The whole mammary gland staining was carried out essentially as described in histological techniques 'http://mammary.nih.-gov/tools/histological/histology/index.html' except that mammary glands were incubated in acetone for 30 min after Carnoy's fixation. Xylene-cleared tissue was placed in methylsalicylate for microscopic analysis and photography.
Histopathology and IHC
Tissue specimens were fixed with 4% formaldehyde solution containing 1% acetic acid or Bouin's solution and embedded in Paraplast X-TRA (Sherwood Medical). Deparaffinated sections were stained with H&E (Sigma) and periodic acid-Schiff reaction (PAS) (Sigma) according to standard laboratory protocols.
For the immunohistochemical demonstration of influenza virus hemagglutinin (HA-tag), SV40 large T-antigen, and wtp53 on paraffin sections, a two-step immunoenzymatic method was used. For antigen demasking, deparaffinated sections were treated with heat in a commercial pressure cooker in the presence of an antigen retrieval solution Citra Plus (Biogenex). Sections were then incubated overnight at 41C with appropriately diluted polyclonal rabbit antibodies against HA-tag (MoBiTec), denatured SV40 large T-antigen (designated R15 anti-SDS-T, Deppert and Pates, 1979) , and wtp53 (purchased from the Scottish Antibody Production Unit, SAPU). Specifically bound primary antibodies were detected using a highly sensitive alkaline phospatase-and polymer-conjugated anti-rabbit Ig detection system (Envision, DakoCytomation, and Histofine, Nichirei, respectively). Alkaline phospatase activity was visualized using naphthol AS-BI-phosphate and New Fuchsin (Fuchsin plus substrate-chromogene, DakoCytomation) as substrate. Finally sections were counterstained with hemalum and permanently coverslipped.
For the simultaneous demonstration of SV40 large Tantigen and influenza virus hemagglutinin (HA-tag), an indirect immunofluorescence labeling technique was employed. Deparaffinated sections were incubated overnight with an antibody cocktail containing diluted guinea-pig antiserum against denatured SV40 large T-antigen (designated gp #21, laboratory W. Deppert) and diluted rabbit anti-HA-tag antibodies (MoBiTec). Then, specifically bound guinea-pig and rabbit antibodies were separately made visible by first incubating the sections with affinity-purified Cy2-conjugated donkey anti-rabbit IgG (H þ L) (Jackson-Dianova) followed by affinity-purified Cy3-conjugated donkey anti-guinea pig IgG (H þ L) (Jackson-Dianova). The fluorescently labeled sections were viewed under a Leica DMRA fluorescence microscope equipped with appropiate filter systems and digital micrographs were captured by the help of a CCD microscope camera (Spot camera, INTAS, Go¨ttingen).
For indirect immunofluorescence in cell culture experiments, cells were plated in a six-well culture plate containing coverslips. The paraformaldehyde fixation and conventional immunostaining of cells was carried out according to standard procedures. The cell preparations were examined on a Zeiss LSM 510 META confocal laser scanning microscope. Primary antibodies used in this study were monoclonal rat anti-EpCam (1 : 100; BD Biosciences Pharmingen) and mouse monoclonal anti-cytokeratin (mab cocktail) (1 : 100, Sigma). Fluochromeconjugated secondary antibodies were obtained from Dianova and Molecular Probes Europe BV.
Cells and abortive infection
Murine BALB/c 3T3 cells were grown in DMEM (Gibco) containing 5% FCS (PAA). Stable 3T3mutp53 C2 and C6 clones were maintained in DMEM supplemented with 5% FCS and 200 mg/ml G418 (Gibco). Cells were grown to subconfluent monolayers in 100 mm 2 dishes and infected with SV40 virus (strain 776) at a multiplicity of infection (MOI) of one, as previously described (Tiemann and Deppert, 1994) . Virus incubation (2 h) at 371C continued altogether in complete medium for 34 h postinfection.
Chloroquine treatment
Cells were plated the day before and grown to a confluence of about 70% in 150 mm 2 dishes in 20 ml culture medium (see above). At 24 h after plating, 50 mM chloroquine (Sigma) was added to the culture medium and cells were incubated for additional 24 and 48 h. Cultured cells were harvested and analysed by Western blotting.
Western blot analysis
Whole-cell protein extracts were obtained by cell lysis with 50 mM HEPES/KOH (pH 7.4), 150 mM NaCl, 0.1% NP-40, 5 mg/ml leupeptin, 10 mg/ml pepstatin A, 250 mg/ml pefablock SC, and 1% trasylol. Equal amounts of protein (40 mg per lane) were separated by SDS-PAGE (13%) and transferred on a PVDF membrane (Immobilon-P, Millipore). For details, see Heinrichs and Deppert (2003) . Mutp53 expression was detected with the monoclonal rat Anti-HA High Affinity antibody (1 : 1000, clone 3F10, Roche). SV40 large T-antigen expression was detected using polyclonal rabbit antibody designated R15 anti-SDS-T (1 : 5000, Deppert and Pates, 1979) . For control of equal protein loading, membranes were reprobed with monoclonal mouse anti-a-tubulin antibody (1 : 5000, Oncogene Research). Horseradish-peroxidase (HRP)-coupled secondary donkey-anti-rat (1 : 5000), donkeyanti-rabbit (1 : 10000) and donkey-anti-mouse (1 : 10000) antibodies were obtained from Rockland. Protein bands were generally visualized using enhanced chemoluminescence (ECL) detection reagents (Deppert laboratory) and in the case of mutp53 using Super Signal West Dura Extended Duration Substrate (Pierce Biotechnology).
In situ hybridization
Mouse mammary epithelial cell culture was established according to Smalley et al. (1998) from a tumor of a bitransgenic WAP-T1 Â WAP-mutp53 R270H -H22 mouse, and propagated in DMEM/10% FCS medium supplemented with 5 mg/ml insulin, hydrocortisone, prolactin, and b-estradiol (all from Sigma) at 371C, 5% CO 2 . Cells grown on glass coverslips were washed twice in PBS and subsequently fixed in 3.7% paraformaldehyde in PBS for 10 min at room temperature (RT). Then, the cells were permeabilized with SDS-buffer (0.05% SDS, 100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 12.5 mM EDTA) for 10 min at RT, rinsed twice with PBS and 2 Â SSC buffer (3 Â 20 min). The hybridization mixture was prepared by dissolving (per coverslip) 20 pmol biotinylated (CCCTAA) 3 telomere-peptide nucleic acid (PNA) probe (Perkin-Elmer Biosystems), 20 ng of digoxigenin-labeled, mouse g-satellite-specific dsDNA probe and 5 mg of competitor salmon sperm DNA (Sigma) in 10 ml of 50% formamide. After heating for 5 min at 901C and rapid chilling in ice water, the solution was supplemented with formamide, SSC buffer, and Tris-HCl, pH 7.5 to achieve final concentrations of the additives of 50%, 2 Â , and 50 mM, respectively. Digoxigenin-labeled DNA probe was produced by amplification of plasmid-inserted, desminbound DNA fragment DesB25 (Tolstonog et al., 2000) with vector-specific primers and digoxigenin-11-dUTP (Roche). Hybridization mixture was dropped onto the slides, covered with glass coverslips and sealed with rubber cement. Hybridization was performed at following condition: denaturation at 901C, 5 min and annealing at 421C, 16 h. After hybridization, the cells were washed three times for 20 min with 2 Â SSC at 371C and once with 0.5 Â SSC for 15 min at RT. SV40 large T-antigen, digoxigenin, and biotin were detected with PAb419 (1 : 100) followed by donkey antimouse-Cy5 (1 : 100; Dianova), anti-digoxigenin-rhodamine (1 : 200; Roche), and fluorescein avidin DN (1 : 400; Alexis), respectively, according to standard procedure for immunnofluorescence staining. Coverslips were mounted with Vectashield (Alexis), and examined on a Zeiss LSM 510 META confocal laser scanning microscope. Confocal image data were processed with Adobe Photoshop 7.0 imaging software (Adobe Systems).
